Cardiovascular Outcomes with Sotagliflozin

To the Editor: In the SOLOIST-WHF trial (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure), Bhatt et al. (Jan. 14 issue) 1 report that death from cardiovascular causes and hospitalizations and urgent visits for heart failure (the composit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 384; číslo 15; s. 1470 - 1473
Hlavní autoři: Baglioni, Piero, Marchand, Lucien, Villar, Emmanuel, Green, Lisa, Bhatt, Deepak L, Steg, P. Gabriel, Pitt, Bertram
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 15.04.2021
Témata:
Cardiovascular diseases
Congestive heart failure
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetic Ketoacidosis
Glycosides
Heart failure
Humans
Mortality
Placebos
Renal Insufficiency, Chronic
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:To the Editor: In the SOLOIST-WHF trial (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure), Bhatt et al. (Jan. 14 issue) 1 report that death from cardiovascular causes and hospitalizations and urgent visits for heart failure (the composite primary outcome) occurred in fewer patients in the sotagliflozin group than in the placebo group. This benefit was also seen in the SCORED trial (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) reported by Bhatt et al. (also in Jan. . . .
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Commentary-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2102961